Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavoglurant in Alcohol Drinking
NCT03327792Phase 1Completed
- Sponsor
- Yale University
- Start
- Feb 2018
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in alcohol use disorder (AUD) comparing 200 mg Mavoglurant with Placebo (2 arms). Primary endpoint: Abnormal Labs and Adverse Events at Day 10. Started Feb 2018; status: completed.
02
Drugs
mavoglurant
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03327792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03327792.